PD-1 and PD-L1 targeting immune checkpoint inhibition has been shown to directly influence TIL-Bs, as evidenced by the presence of PD-1+ and PD-L1+ TIL-Bs in a number of human malignancies, including breast cancer and hepatoma (161–164). The gene discussed is CD274; the disease is breast carcinoma.